Medicina de precisión en sepsis: utilidad de los biomarcadores en pacientes biomarcadores en pacientes críticamente enfermos

dc.creatorMolano Franco, Daniel
dc.creatorGómez Duque, Mario
dc.creatorBeltrán, Edgar
dc.creatorVillabón González, Mario
dc.creatorRobayo Valbuena, Ivan Felipe
dc.creatorFranco, Luis Felipe
dc.creatorCárdenas Colmenares, Jorge Alberto
dc.creatorEstupiñán Monsalve, Álvaro
dc.creatorSánchez Vanegas, Guillermo
dc.creatorArévalo Rodriguez, Ingrid
dc.creatorZamora Romero, Javier
dc.date.accessioned2020-08-18 13:11:22
dc.date.accessioned2022-06-29T19:38:11Z
dc.date.accessioned2022-09-27T12:37:20Z
dc.date.available2020-08-18 13:11:22
dc.date.available2022-06-29T19:38:11Z
dc.date.available2022-09-27T12:37:20Z
dc.date.created2020-08-18 13:11:22
dc.date.created2022-06-29T19:38:11Z
dc.date.issued2020-08-18
dc.identifier10.31260/RepertMedCir.01217273.973
dc.identifier0121-7372
dc.identifierhttps://repositorio.fucsalud.edu.co/handle/001/2947
dc.identifier2462-991X
dc.identifierhttps://doi.org/10.31260/RepertMedCir.01217273.973
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3595926
dc.languagespa
dc.publisherSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.relationDellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
dc.relationLevy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250-6.
dc.relationSankar V, Webster NR. Clinical application of sepsis biomarkers. J Anesth. 2013;27(2):269-83.
dc.relationRangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117-23.
dc.relationSinger M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
dc.relationFleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med. 2016;193(3):259-72.
dc.relationCawcutt KA, Peters SG. Severe sepsis and septic shock: clinical overview and update on management. Mayo Clin Proc. 2014;89(11):1572-8.
dc.relationRhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77.
dc.relationWang T, Derhovanessian A, De Cruz S, Belperio JA, Deng JC, Hoo GS. Subsequent infections in survivors of sepsis: epidemiology and outcomes. J Intensive Care Med. 2014;29(2):87-95.
dc.relationWhittaker SA, Fuchs BD, Gaieski DF, Christie JD, Goyal M, Meyer NJ, et al. Epidemiology and outcomes in patients with severe sepsis admitted to the hospital wards. J Crit Care. 2015;30(1):78-84.
dc.relationWunsch H, Guerra C, Barnato AE, Angus DC, Li G, Linde-Zwirble WT. Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA. 2010;303(9):849-56.
dc.relationYende S, Linde-Zwirble W, Mayr F, Weissfeld LA, Reis S, Angus DC. Risk of cardiovascular events in survivors of severe sepsis. Am J Respir Crit Care Med. 2014;189(9):1065-74.
dc.relationHarbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396-402.
dc.relationBone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55.
dc.relationSandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol. 2014;10(10):1349-56.
dc.relationSeymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019;321(20):2003-17.
dc.relationRautanen A, Mills TC, Gordon AC, Hutton P, Steffens M, Nuamah R, et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2015;3(1):53-60.
dc.relationvan Engelen TSR, Wiersinga WJ, Scicluna BP, van der Poll T. Biomarkers in Sepsis. Crit Care Clin. 2018;34(1):139-52.
dc.relationRello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, et al. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2018;24(12):1264-72.
dc.relationKibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66 Suppl 2:ii33-40.
dc.relationMolano Franco D, Arevalo‐Rodriguez I, Roqué i Figuls M, Zamora J. Interleukin‐6 for diagnosis of sepsis in critically ill adult patients. The Cochrane Database of Systematic Reviews. 2015;2015(7):CD011811.
dc.relationOnyenekwu CP, Okwundu CI, Ochodo EA. Procalcitonin, C‐reactive protein, and presepsin for the diagnosis of sepsis in adults and children. Cochrane Database of Systematic Reviews. 2017(4) :CD012627. doi: 10.1002/14651858.CD012627.
dc.relationLiu Y, Hou JH, Li Q, Chen KJ, Wang SN, Wang JM. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis. Springerplus. 2016;5(1):2091.
dc.relationHoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015;21(5):474-81.
dc.relationLee SH, Chan RC, Wu JY, Chen HW, Chang SS, Lee CC. Diagnostic value of procalcitonin for bacterial infection in elderly patients - a systemic review and meta-analysis. Int J Clin Pract. 2013;67(12):1350-7.
dc.relationLiu D, Su L, Han G, Yan P, Xie L. Prognostic Value of Procalcitonin in Adult Patients with Sepsis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(6):e0129450.
dc.relationSchuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care. 2007;13(5):578-85.
dc.relationMartínez-Sagasti F, Velasco-López E, Domingo-Marín S, Gil-Perdomo JM. Usefulness of biomarkers on infection management: with or without them? Rev Esp Quimioter. 2018;31 Suppl 1:43-6.
dc.relationDebiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang Y, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med. 2014;42(12):2500-7.
dc.relationMasson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18(1):R6.
dc.relationHiggins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration: The Cochrane Collaboration; 2011.
dc.relationGiannakopoulos K, Hoffmann U, Ansari U, Bertsch T, Borggrefe M, Akin I, et al. The Use of Biomarkers in Sepsis: A Systematic Review. Curr Pharm Biotechnol. 2017;18(6):499-507.
dc.relationWu Y, Wang F, Fan X, Bao R, Bo L, Li J, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care. 2012;16(6):R229.
dc.relationKofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
dc.relationRoldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990;9(2):467-74.
dc.relationWittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect. 2004;10(5):409-15.
dc.relationSavva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63(5):344-50.
dc.relationGiamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16(4):R149.
dc.relationKumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-96.
dc.relationMolano Franco D ARI, Sanchez G, Gomez M, Villabon, M NX, Ferrer R, Beltran Linares E, Costa T, Zamora J. Sepsis biomarkers for prognosis of critically ill adult patients: a suite of prognostic factors systematic reviews. Prospero. 2019.
dc.relationGentile LF, Cuenca AG, Vanzant EL, Efron PA, McKinley B, Moore F, et al. Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods. 2013;61(1):3-9.
dc.relationCabioglu N, Bilgic S, Deniz G, Aktas E, Seyhun Y, Turna A, et al. Decreased cytokine expression in peripheral blood leukocytes of patients with severe sepsis. Arch Surg. 2002;137(9):1037-43; discussion 43.
dc.relationWunder C, Eichelbrönner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res. 2004;53(4):158-63.
dc.relationPallás Beneyto LA, Rodríguez Luis O, Saiz Sánchez C, Coltell O, Bautista Rentero D, Miguel Bayarri V. [Prognostic value of interleukin 6 for death of patients with sepsis]. Med Clin (Barc). 2016;147(7):281-6.
dc.relationTsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2012;43(1):97-106.
dc.relationOberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, et al. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock. 2005;23(6):488-93.
dc.relationLarsen FF, Petersen JA. Novel biomarkers for sepsis: A narrative review. Eur J Intern Med. 2017;45:46-50.
dc.relationSager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15(1):15.
dc.relationPrado-Díaz A, Castillo A, Rojas DM, Chávez-Vivas M. Marcadores moleculares en el diagnóstico y pronóstico de sepsis, sepsis grave y choque séptico. Revista de la Facultad de Medicina.2017;65:145-55.
dc.relationGriselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190(12):1733-40.
dc.relationMortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res. 2001;24(2):163-76.
dc.relationVolanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2-3):189-97.
dc.relationMorley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406-18.
dc.relationMacy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43(1):52-8.
dc.relationPepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12.
dc.relationPóvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect. 2005;11(2):101-8.
dc.relationBalcI C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care. 2003;7(1):85-90.
dc.relationCarrillo Esper R, Pérez Calatayud ÁA. Procalcitonina como marcador de procesos infecciosos en cirugía. Conceptos actuales. Cirujano general. 2013;35(1):49-55.
dc.relationWacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-35.
dc.relationVijayan AL, Vanimaya, Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care. 2017;5:51.
dc.relationSchuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-66.
dc.relationBouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5):1-12.
dc.relationPeat G, Riley RD, Croft P, Morley KI, Kyzas PA, Moons KG, et al. Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. PLoS Med. 2014;11(7):e1001671.
dc.relationSaavedra Ramírez PG, Vásquez Duque GM, González Naranjo LA. Interleucina-6: ¿amiga o enemiga? Bases para comprender su utilidad como objetivo terapéutico. Iatreia; Vol 24, Núm 2. 2011.
dc.relationNishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nature Clinical Practice Rheumatology. 2006;2(11):619-26.
dc.relationKimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-5.
dc.relationKishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347-52.
dc.relationGabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8 Suppl 2:S3.
dc.relationJiang Y, Liu AH, Huang QB. p38 MAPK Signal is Necessary for TNF-alpha Gene Expression in RAW Cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1999;31(1):9-15.
dc.relationZou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5(1):16-9.
dc.relationCamargo, Rubio R FCD, Thomae R, Alcocer Olaciregui A, Vargas Moranth R. Diagnóstico y pronóstico de sepsis con presepsina en el Departamento de Urgencias. Acta Colomb Cuid Intensivo 2018;18(2):92-9.
dc.relationGiavarina D, Carta M. Determination of reference interval for presepsin, an early marker for sepsis. Biochem Med (Zagreb). 2015;25(1):64-8.
dc.relationWu J, Hu L, Zhang G, Wu F, He T. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(7):e0133057.
dc.relationKanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm. 2004;13(5-6):313-9.
dc.relationØstervig RM, Køber L, Forberg JL, Rasmussen LS, Eugen-Olsen J, Iversen K. SuPAR - A future prognostic biomarker in emergency medicine. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2015;23(Suppl 1):A31-A.
dc.relationMolano Franco D AI, Sanchez G, Gomez M, Villabon M, Nubials X, Ferrer R, Beltran Linares E, Costa T, Zamora J. Sepsis biomarkers for prognosis of critically ill adult patients: a suite of prognostic factors systematic reviews. Prospero. 2019.
dc.relationhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/973/1176
dc.relationhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/973/1306
dc.relationhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/973/1305
dc.relationhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/973/1293
dc.relationhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/973/1311
dc.relationNúm. 2 , Año 2020 : Mayo - Agosto
dc.relation83
dc.relation2
dc.relation75
dc.relation29
dc.relationRevista Repertorio de Medicina y Cirugía
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rightsRevista Repertorio de Medicina y Cirugía - 2020
dc.sourcehttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/973
dc.subjectmedicina de precisión
dc.subjectbiomarcador
dc.subjectsepsis
dc.subjectInterleuquina 6
dc.subjectproteína C reactiva
dc.subjectprocalcitonina
dc.subjectpresepsina
dc.subjectdiagnóstico
dc.subjectpronóstico
dc.subjectPrecision medicine
dc.subjectbiomarker
dc.subjectsepsis
dc.subjectInterleukin-6
dc.subjectC-reactive protein
dc.subjectprocalcitonin
dc.subjectpresepsin
dc.subjectdiagnosis
dc.subjectprognosis
dc.titleMedicina de precisión en sepsis: utilidad de los biomarcadores en pacientes biomarcadores en pacientes críticamente enfermos
dc.typeArtículo de revista
dc.typeJournal article


Este ítem pertenece a la siguiente institución